REGN (Regeneron Pharmaceuticals) Kacepetan wutah bathi saben saham ing taun lumaku

REGN (regeneron.com) - tandha merek perusahaan

Regeneron Pharmaceuticals (REGN) ensures operational stability through its own high-tech manufacturing plants in the US and Ireland. The annual growth rate of net income per share demonstrates the market consensus, where 54.20 reflects the latest value of the metric. Dominance in the sector is sustained by patents on blockbuster drugs, while success is based on unique genetic developments that defeat severe diseases.

REGN (Regeneron Pharmaceuticals) riwayat Wutah bathi saben saham ing taun lumaku saka 04.07.2022 nganti 18.11.2026

Rincian metrik komprehensif lan analitis Regeneron (REGN)

Analisis dhasar perusahaan:Regeneron Inc. REGN
Produk merek regeneron.com

This indicator measures the annual growth rate of earnings per share, allowing for an assessment of business scaling efficiency and the pace of capital generation. By analyzing EPS dynamics compared to the previous year, an investor can identify risks of revenue stagnation for Regeneron Pharmaceuticals (REGN) due to biosimilar expansion or clinical trial failures, which is critical for the long-term valuation of the asset.